1 Small cell-免疫表型特征 主要是靠CD5, CD10, CD23, CD25, CD103, cyclin D来层级分类(图1)。 图1 Small cell分类流程图 2 Medium cell-免疫表型特征 基本同上,增加了增殖指标Ki67(图2)。 图2 Medium cell分类流程图 3 Large cell-免疫...
[4]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-lunsumio-mosunetuzumab-axgb-adult-patients-relapsed-or. [5]NCCN Guidelines Version 1.2020:B-cell Lymphomas. ...
1 Small cell-免疫表型特征 主要是靠CD5, CD10, CD23, CD25, CD103, cyclin D来层级分类(图1)。 图1 Small cell分类流程图 2 Medium cell-免疫表型特征 基本同上,增加了增殖指标Ki67(图2)。 图2 Medium cell分类流程图 3 Large cell-免疫表型特征 主要靠CD5, CD10, CD103, IRF4/MUM1来分类(图3)...
参考文献 Saifi O, et al.Outcomes of r/r B-cell NHL patients with limited (<5 Sites) pre-CART Disease Bridged With or Without Radiotherapy.Blood Adv . 2024 Jul 19:bloodadvances.2024013647. doi: 10.1182/bloodadvances.2024013647.
轉錄共激活因子P300Raji cell curcumintranscriptional co-activator P300Raji cellAim To investigate the effect of curcumin relating transcriptional co-activator P300 on B-NHL cell line Raji, and to study anti-proliferative molecular machenism of curcumin on Raji cells. Methods Raji cells in cultured in ...
近日，来自美国俄亥俄州立大学综合癌症中心的Jennifer A. Woyach教授领衔和Merck公司的团队联合在Cancer Discovery杂志上发表文章First in Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma。这项首次人体I期...
【Cell Oncol】CAR-T治疗r/r B-NHL后PD1抑制剂维持治疗的疗效 CAR-T后PD1维持治疗。 CAR-T细胞疗法在复发/难治(r/r) B细胞非霍奇金淋巴瘤(B-NHL)的治疗中获得成功,但仅有30%~40%的患者获得长期缓解。 研究显示,CAR-T细胞与PD1抑制剂联合应用可增强CAR-T细胞的扩增、持久性和杀伤功能。
EP: 1.Epcoritamab Inducing Complete Responses in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Martin Hutchings, MD, PhD, presents slides from the 62nd ASH Annual Meeting and Exposition for the phase 1/2 study for epcoritamab inducing complete responses in relapsed/refractory B-cell non-Hodgki...
非霍奇金淋巴瘤(non-Hodgkin lymphoma, NHL)是常见的恶性肿瘤之一,其中最常见的病理类型为弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma, DLBCL)。经过一线标准治疗,约50%~60%的DLBCL患者可以治愈。对于复发或难治DLBCL患者,有条件的患者可以选择挽救化疗联合自体干细胞移植。但在实际临床操作过程中,患者可能不符...
Paolo Caimi, MD, discusses the rationale behind evaluating LMY-920, a novel BAFF CAR T-cell therapy, in relapsed/refractory non-Hodgkin lymphoma. Video Player is loading. This is a modal window. This video is either unavailable or not supported in this browser Error Cod...